VTV Therapeutics Starts Phase 3 Trial of T1D Drug
VTV Therapeutics has initiated its Phase 3 CATT1 trial, evaluating cadisegliatin as an oral adjunctive therapy to insulin for...
Jon Napitupulu
SciSparc, Clearmind File International Patent for Obesity, Blood Sugar Combination Therapy
Scisparc and Clearmind Secure Patent for Combination Therapy Targeting Obesity and Metabolic Syndrome Scisparc and Clearmind have announced a...
Cormedix Acquires Melinta, Creating Diversified Specialty Company
Cormedix’s acquisition of Melinta Therapeutics for $300 million, plus potential milestones and royalties, marks a decisive shift in the...
Pure Harvest Eliminates Debt, Enters Strategic Growth Phase
Pure Harvest Corporate Group, Inc. (PHCG) has achieved a significant milestone by eliminating all debt from its balance sheet....
FDA Approves Ajovy for Pediatric Episodic Migraine
Teva Pharmaceuticals has secured FDA approval for Ajovy (fremanezumab) as a preventative treatment for episodic migraine in children and...
Omass Therapeutics Appoints Non-Executive Director & Audit Chair
Omass Therapeutics, a UK-based biotech specializing in targeting complex protein ecosystems, has appointed Carol A. Schafer as Non-Executive Director...
Nxera Launches Proprietary Pipeline for Obesity and Weight Management
Nxera Pharma is boldly expanding its pipeline beyond partnerships into a wholly owned portfolio of next-generation obesity and metabolic...
TG Therapeutics Raises Briumvi Revenue Guidance After Q2 2025 Results
TG Therapeutics Reports Strong Q2 2025 Briumvi Sales, Raises Full-Year Guidance TG Therapeutics announced impressive second-quarter 2025 results, driven...
Connect Appoints New CEO to Drive Innovation and Growth
Connect, a cornerstone of San Diego’s life science and technology ecosystem, has appointed James Zanewicz as its new CEO....
Artelo Biosciences Adopts Solana as Core Reserve Asset
Artelo Biosciences is making a bold move, becoming the first publicly traded pharmaceutical company to adopt Solana (SOL) as...